NeuroSense Files Routine 6-K with March 24, 2026 Press Release
Ticker: NRSN · Form: 6-K · Filed: Mar 24, 2026 · CIK: 0001875091
| Field | Detail |
|---|---|
| Company | Neurosense Therapeutics LTD. (NRSN) |
| Form Type | 6-K |
| Filed Date | Mar 24, 2026 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, press-release, foreign-issuer
TL;DR
**NeuroSense filed a 6-K with a press release, check EX-99.1 for news.**
AI Summary
NeuroSense Therapeutics Ltd. filed a 6-K on March 24, 2026, which included a press release dated the same day. This filing, identified by SEC Accession No. 0001213900-26-033270, is a routine report for foreign private issuers and does not contain specific financial or operational updates beyond the existence of the press release. For investors, this means there's no new material information directly in the 6-K itself, but the accompanying press release (EX-99.1) might contain important news that could impact the stock's value.
Why It Matters
This filing is a standard report for foreign companies, indicating that NeuroSense has released a press statement on March 24, 2026, which could contain new developments relevant to investors.
Risk Assessment
Risk Level: low — This 6-K filing is a routine administrative report and does not inherently present new financial or operational risks.
Analyst Insight
A smart investor would review the attached press release (EX-99.1) dated March 24, 2026, to understand any new developments or announcements made by NeuroSense Therapeutics Ltd., as the 6-K itself is primarily an administrative notification.
Key Numbers
- 2026-03-24 — Filing Date (The date the 6-K was filed and accepted by the SEC.)
- 3 — Documents (The number of documents included in the filing (6-K, Press Release, Graphic).)
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — the filer of the 6-K
- 0001875091 (company) — CIK of NeuroSense Therapeutics Ltd.
- 0001213900-26-033270 (dollar_amount) — SEC Accession No. for the filing
FAQ
What is the purpose of this 6-K filing by NeuroSense Therapeutics Ltd.?
This 6-K filing is a 'Report of foreign issuer' under Rules 13a-16 and 15d-16, which is a routine report for foreign private issuers. It indicates that NeuroSense Therapeutics Ltd. has made a public announcement, specifically a press release dated March 24, 2026, which is included as Exhibit 99.1.
What specific documents are included in this 6-K filing?
The filing includes three documents: the 'REPORT OF FOREIGN PRIVATE ISSUER' (ea0283188-6k_neurosense.htm), a 'PRESS RELEASE DATED MARCH 24, 2026' (ea028318801ex99-1.htm), and a 'GRAPHIC' (ea028318801_ex99-1img1.jpg).
Filing Stats: 270 words · 1 min read · ~1 pages · Grade level 10.1 · Accepted 2026-03-24 10:11:22
Filing Documents
- ea0283188-6k_neurosense.htm (6-K) — 11KB
- ea028318801ex99-1.htm (EX-99.1) — 14KB
- ea028318801_ex99-1img1.jpg (GRAPHIC) — 27KB
- 0001213900-26-033270.txt ( ) — 63KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: March 24, 2026 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 3